scanX
Home
Jubilant Pharmova

Jubilant Pharmova

866.45
+1.45
(0.17%)
Market Cap
13,800.91 Cr
EPS
4.87
PE Ratio
40.89
Dividend Yield
0.58 %
Industry
Healthcare
52 Week High
1,309.90
52 Week low
538.05
PB Ratio
2.32
Debt to Equity
0.68
Add Ratio
Live Chart

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from2 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy100.00 %
100.00 %
Hold0.0 %
0.0 %
Sell0.0 %
0.0 %

Company News

View All News
Caret
positive
Jubilant Cadista Facility Receives EIR with VAI Status from USFDA1 day ago
Jubilant Pharmova announced that its Jubilant Cadista facility has successfully closed an inspection by the United States Food and Drug Administration (USFDA). The facility received an Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) status, indicating that the inspection was concluded satisfactorily.
neutral
Jubilant Pharmova: FDA Closes Inspection of Maryland Facility with VAI Status1 day ago
Jubilant Cadista Pharmaceuticals, a subsidiary of Jubilant Pharmova, received an Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) status from the USFDA for its Maryland facility. The inspection, conducted in January 2025, is now closed. However, the facility's manufacturing operations were previously shut down in April 2024.
positive
Jubilant Cadista Facility Receives EIR with VAI Status from USFDA1 day ago
Jubilant Pharmova announced that its Jubilant Cadista facility has successfully closed an inspection by the U.S. Food and Drug Administration (USFDA). The facility received an Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) status, indicating that the inspection was concluded satisfactorily.

Peer Comparison Compare Peers on Screener

Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
Sun Pharmaceutical
 1,683.45 4,03,916.05 34.10 49,887.20 12.06 9,648 13.77 52.67
Divis Laboratories
 5,620.45 1,49,205.29 72.77 8,184.00 0.89 1,600 64.53 45.57
Cipla
 1,461.90 1,18,065.10 23.53 26,520.70 14.17 4,155 47.38 52.92
Torrent Pharmaceuticals
 3,056.05 1,03,430.62 56.27 10,785.70 11.59 1,656 13.54 47.23
Dr Reddys Laboratories
 1,107.95 92,448.55 17.17 28,905.40 12.36 5,578 1.69 30.37
Mankind Pharma
 2,201.15 90,812.16 43.84 10,615.60 19.57 1,942 -16.38 35.15
Lupin
 1,968.45 89,800.21 31.28 20,141.50 19.94 1,936 38.82 43.62
Zydus Life Science
 883.10 88,860.52 19.73 19,831.50 13.82 3,831 29.92 40.81
Aurobindo Pharma
 1,094.75 63,583.26 18.24 29,559.20 17.55 3,169 -10.04 43.94
Abbott
 29,597.00 62,891.56 47.49 6,097.20 10.80 1,201 16.01 49.75
Growth Rate
Revenue Growth
7.15 %
Net Income Growth
-212.02 %
Cash Flow Change
47.01 %
ROE
-211.67 %
ROCE
99.13 %
EBITDA Margin (Avg.)
11.09 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Revenue
1,529
1,430
1,439
1,327
1,466
1,405
1,365
1,444
1,576
1,545
1,628
2,045
2,247
2,056
2,249
2,382
2,346
2,163
2,249
1,544
1,563
1,175
1,631
1,838
1,614
1,617
1,638
1,304
1,513
1,452
1,598
1,543
1,682
1,575
1,686
1,714
1,764
2,130
1,764
1,823
Expenses
1,323
1,121
1,129
1,061
1,192
1,051
1,045
1,126
1,293
1,219
1,336
1,651
1,794
1,663
1,828
1,899
2,262
1,747
1,798
1,141
1,131
977
1,242
1,293
1,216
1,269
1,319
1,116
1,280
1,259
1,440
1,408
1,459
1,419
1,439
1,459
1,656
1,480
1,477
1,554
EBITDA
206
309
310
266
274
354
319
318
283
327
293
394
453
393
422
483
83
415
451
403
432
199
389
546
398
348
319
187
233
192
158
134
223
156
247
255
108
650
287
269
Operating Profit %
13 %
21 %
21 %
20 %
19 %
25 %
23 %
22 %
17 %
21 %
18 %
19 %
19 %
19 %
19 %
19 %
4 %
19 %
20 %
24 %
24 %
13 %
20 %
26 %
22 %
21 %
19 %
14 %
15 %
13 %
9 %
8 %
12 %
9 %
14 %
12 %
5 %
14 %
15 %
14 %
Depreciation
66
70
75
75
127
72
72
73
75
73
79
82
182
88
90
98
95
103
117
84
98
82
85
96
86
88
100
93
101
95
94
94
271
90
97
95
101
91
91
91
Interest
85
91
92
89
99
83
80
98
80
69
66
77
73
51
54
53
62
73
72
49
47
48
47
46
43
35
35
37
40
40
42
51
56
62
66
71
73
71
61
56
Profit Before Tax
68
168
161
145
69
218
193
166
160
203
168
261
227
286
302
356
-40
269
292
294
358
106
299
431
297
247
208
70
106
69
36
9
-86
25
98
101
-54
500
144
131
Tax
25
37
36
24
58
54
50
48
11
60
43
48
74
86
92
88
61
84
43
90
98
18
75
121
83
86
65
19
47
22
32
25
14
19
36
35
8
18
42
30
Net Profit
43
130
125
122
11
164
144
118
149
144
126
213
152
200
210
268
-101
185
249
203
261
88
224
310
214
161
143
51
59
47
5
-16
-101
6
62
66
-62
482
103
101
EPS in ₹
2.68
8.28
8.11
7.90
0.72
10.39
9.29
7.66
9.63
9.44
8.23
13.64
9.94
13.00
13.50
16.74
-6.38
11.61
15.66
12.77
16.35
5.53
14.06
19.46
13.43
10.09
8.97
3.20
3.74
2.96
0.34
-0.98
-6.15
0.40
3.94
4.22
-3.69
30.44
6.47
6.37
Above figures are in Rs. Crores

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Total Assets
8,619
8,824
9,041
9,618
11,469
12,522
8,918
9,991
11,157
11,549
Fixed Assets
4,911
5,104
5,107
5,401
5,648
6,340
4,609
4,871
5,183
5,091
Current Assets
2,715
2,875
2,948
3,190
4,585
5,038
2,953
3,509
3,762
3,876
Capital Work in Progress
597
611
684
671
901
768
897
1,090
1,562
2,103
Investments
0
85
103
124
115
69
241
239
256
42
Other Assets
3,111
3,023
3,147
3,423
4,804
5,344
3,171
3,792
4,156
4,312
Total Liabilities
8,619
8,824
9,041
9,618
11,469
12,522
8,918
9,991
11,157
11,549
Current Liabilities
2,129
2,464
1,684
2,005
2,090
2,619
1,049
1,592
1,772
1,889
Non Current Liabilities
4,036
3,432
3,968
3,578
4,570
4,299
3,128
3,083
3,993
4,238
Total Equity
2,454
2,928
3,389
4,035
4,809
5,604
4,742
5,316
5,392
5,421
Reserve & Surplus
2,438
2,951
3,421
4,071
4,793
5,588
4,726
5,303
5,383
5,418
Share Capital
16
16
16
16
16
16
16
16
16
16
Above figures are in Rs. Crores

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
-82
-52
117
-212
761
225
-652
482
30
-58
Investing Activities
-362
-309
-465
-614
-1,018
-267
-727
-323
-474
-596
Operating Activities
783
1,099
1,269
1,303
1,122
1,543
1,784
838
661
971
Financing Activities
-503
-843
-686
-901
657
-1,050
-1,709
-33
-157
-433
Above figures are in Rs. Crores

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Promoter
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
23.21 %
0.00 %
19.06 %
19.49 %
17.94 %
16.96 %
DIIs
0.78 %
1.15 %
0.40 %
0.43 %
0.05 %
0.04 %
0.39 %
1.62 %
0.40 %
1.63 %
1.65 %
1.50 %
3.78 %
4.07 %
5.66 %
6.98 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
1.24 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
16.07 %
16.98 %
19.03 %
18.97 %
19.27 %
19.35 %
19.01 %
18.68 %
18.69 %
18.25 %
18.24 %
18.76 %
18.71 %
17.79 %
18.09 %
18.09 %
Others
32.47 %
31.19 %
29.89 %
29.92 %
30.00 %
29.93 %
29.92 %
29.02 %
28.98 %
29.44 %
6.22 %
29.06 %
7.77 %
7.97 %
7.63 %
7.30 %
No of Share Holders
0
61,942
87,493
1,13,776
1,09,420
1,08,063
1,09,410
1,05,632
97,935
93,375
89,376
86,588
92,264
81,992
89,456
1,02,442

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 3 3 4.5 5 5 5 5 5 0.00
Dividend Yield (%) 0.00 0.36 0.45 1.81 0.73 1.29 1.79 0.88 0.58 0.00

Corporate Action

Announcements

Announcement Under Regulation 30 - USFDA Report For Jubilant Cadista Pharmaceuticals Inc. USA
1 day ago
Rumour verification - Regulation 30(11)
Feb 25, 2025, 12:40
Rumour verification - Regulation 30(11)
Feb 25, 2025, 12:40
Audio Recording Of Investors / Analysts Meeting
Feb 24, 2025, 23:55
Presentation For Investor And Analyst Meet
Feb 24, 2025, 16:50
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Feb 05, 2025, 17:10
Announcement under Regulation 30 (LODR)-Newspaper Publication
Feb 01, 2025, 23:21
Integrated Filing (Financial)
Jan 31, 2025, 17:30
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Jan 31, 2025, 13:17
Unaudited Results For The Quarter Ended December 31 2024
Jan 31, 2025, 13:05
Board Meeting Outcome for Outcome Of Board Meeting
Jan 31, 2025, 13:00
Announcement Under Regulation 30 - Jubilant Biosys Innovative Research Services Pte Limited Singapore (JBIRSPL) A Subsidiary Of Jubilant Biosys Limited A Wholly Owned Subsidiary Of The Company Has Exe
Jan 29, 2025, 24:34
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Jan 27, 2025, 23:26
The Company Has Informed The Prepayment Of USD 25 Million Term Loan Equivalent To Rs. 214 Cr.
Jan 24, 2025, 20:04
Board Meeting Intimation for Intimation For Board Meeting Scheduled On January 31 2025 To Consider The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Nine
Jan 23, 2025, 11:21
USFDA Inspection In Companys Subsidiary Jubilant Cadista Pharmaceuticals Inc.
Jan 17, 2025, 01:01
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Jan 15, 2025, 18:33
Announcement under Regulation 30 (LODR)-Credit Rating
Dec 10, 2024, 18:54
Deferment Of Investor/ Analysts Meeting
Nov 05, 2024, 11:43
Announcement under Regulation 30 (LODR)-Newspaper Publication
Oct 27, 2024, 24:20
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Oct 25, 2024, 13:28
Approval Of Unaudited Financial Results For Quarter And Half Year Ended September 30, 2024
Oct 25, 2024, 12:26
Board Meeting Outcome for Outcome Of The Board Meeting Held On October 25, 2024 - Approval Of Unaudited Financial Results For Quarter And Half Year Ended September 30, 2024
Oct 25, 2024, 12:22
Announcement - Voluntary Prepayment Of USD 25 Million Term Loan, Equivalent To Rs. 210 Cr
Oct 24, 2024, 17:08
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Oct 19, 2024, 14:17
Board Meeting Intimation for Intimation Of Board Meeting
Oct 17, 2024, 18:26
Deletion Of Tax Deman Raised On Jubilant Generics Ltd - Step Down Susbsidiary
Oct 10, 2024, 15:38
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Oct 09, 2024, 17:33
Announcement under Regulation 30 (LODR)-Updates on Acquisition
Oct 04, 2024, 17:51
Announcement under Regulation 30 (LODR)-Change in Management
Oct 01, 2024, 17:02
Announcement Under Regulation 30
Oct 01, 2024, 12:39
Closure of Trading Window
Sep 30, 2024, 17:16
Communication From USFDA
Sep 28, 2024, 19:08
Communication From USFDA.
Sep 26, 2024, 16:31
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Sep 20, 2024, 11:37
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Sep 11, 2024, 18:32
Announcement Under Regulation 30 - Communication From USFDA
Sep 10, 2024, 15:45
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Aug 30, 2024, 18:34
Shareholder Meeting / Postal Ballot-Outcome of AGM
Aug 30, 2024, 18:30
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Aug 24, 2024, 23:56
Postal Ballot Results Alongwith Scrutinizers Report
Aug 23, 2024, 23:53
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Aug 16, 2024, 21:37
Jubilant Biosys Limited, A Wholly Owned Subsidiary Of The Company, Has Signed And Issued A 'Put Option Offer' To Pierre Fabre Laboratories, Which Sets Forth An Offer To Acquire 80% Equity Capital (Approx. Euro 4.4 Million Over A Period Of 2 Years) In A New Company To Be Incorporated In France, Which New Company Shall Acquire Pierre Fabre'S R&D Centre (Including R&D Site And R&D Activities) At Saint Julien, France.
Aug 16, 2024, 17:40
Announcement under Regulation 30 (LODR)-Newspaper Publication
Aug 09, 2024, 18:59
Reg. 34 (1) Annual Report.
Aug 09, 2024, 24:01
Notice Of 46Th Annual General Meeting Alongwith The Annual Report For The Financial Year 2023-24
Aug 08, 2024, 23:49
Business Responsibility and Sustainability Reporting (BRSR)
Aug 08, 2024, 19:48
Announcement under Regulation 30 (LODR)-Newspaper Publication
Aug 06, 2024, 18:00
Announcement under Regulation 30 (LODR)-Change in Management
Aug 02, 2024, 18:56
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Jul 27, 2024, 11:53

Technical Indicators

RSI(14)
Neutral
37.19
ATR(14)
Less Volatile
46.32
STOCH(9,6)
Neutral
20.61
STOCH RSI(14)
Oversold
5.62
MACD(12,26)
Bearish
-5.70
ADX(14)
Weak Trend
17.54
UO(9)
Bearish
37.34
ROC(12)
Downtrend And Accelerating
-10.39
WillR(14)
Oversold
-90.37
Bearish
4
Neutral
4
Bullish
1

About Jubilant Pharmova

Jubilant Pharmova Limited is an integrated global pharmaceutical and life sciences company. It operates in segments including Radiopharma, Allergy Immunotherapy, Contract Development and Manufacturing Organisation-Sterile Injectables, Generics, Contract Research, Development and Manufacturing Organisation, and Proprietary Novel Drugs. The company manufactures and supplies Active Pharmaceutical Ingredients, Solid Dosage Formulations, Radiopharmaceuticals, and Allergy Therapy Products. It has 6 US FDA approved manufacturing facilities in India, USA and Canada, and a network of over 48 radiopharmacies in the USA. Jubilant Pharmova provides drug discovery and development services, and is working on addressing unmet medical needs in oncology and autoimmune diseases. The company has filed numerous Drug Master Files in various countries and has expanded its manufacturing and research capabilities in recent years.
Website
http://www.jubl.com
Chairperson NameShyam S Bhartia
raisewe are part of Raise Financial Services
Heart
built with love

for indians who love to invest & trade

Explore   |   Sitemap
Fundamental Screeners
Price & Volume Screeners
Candlestick Screeners
Technical Screeners
Intraday Screeners
Bullish Stocks Today
Bearish Stocks Today
Stocks Nearing 52W High & Low
Rise & Fall Stocks
Index
Sector
Stock Heatmap
Companies
About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.

© 2025 Moneylicious Securities Pvt. Ltd. All rights reserved.

Part of Raise Financial Services

Corporate Office: A-302, The Western Edge I, Off Western Express Highway, Borivali East, Mumbai – 400066, Maharashtra, India. Land Line: 022-43116666.